Madrigal Pharmaceuticals

Opinion · Devil's advocate

Fact-check-o-meter

Madrigal's sales story holds up in the filings; the clinical framing gets ahead of an accelerated approval

Rezdiffra revenue, cash and the quarterly loss match the 10-Q, the patient count appears only in the release, and the loan terms appear only in the 10-Q. The softer spots are scientific: the release calls Rezdiffra the foundational therapy with efficacy across all subgroups, while the 10-Q says approval rests on 52-week biopsy data with outcomes results not due until 2027 and 2028. No securities litigation is disclosed.

1. Science · weight medium

   "Foundational" and "all subgroups" go beyond the approval basis

   The company said: "continued to generate compelling clinical and real-world evidence that reinforces Rezdiffra as the foundational therapy in MASH that demonstrates efficacy across all patient subgroups." source

   The record says: The 10-Q says the "FDA's accelerated approval and the EC's conditional marketing authorization" were supported by 52-week MAESTRO-NASH data on MASH resolution and fibrosis improvement, and that the trial "remains ongoing as an outcomes trial where we are generating confirmatory outcomes data to 54-months" with data expected in 2028. ClinicalTrials.gov lists a final primary endpoint of "Time to experiencing an adjudicated Composite Clinical Outcome event" at up to 54 months. source

   Our view: The release does not say the U.S. approval is accelerated or that clinical benefit is unconfirmed. The biopsy results are real, but "foundational" is a broader claim than the 52-week biopsy results, and the 10-Q expects outcomes data from MAESTRO-NASH in 2028.

2. Science · weight medium

   Cirrhosis evidence is open-label and modeled

   The company said: "The proportion of patients classified as higher risk for CSPH decreased from 75% at baseline to 54.5% at Year 2." source

   The record says: The release says a risk model "was applied to MAESTRO-NAFLD-1 OLE F4c results", an open-label extension. The 10-Q says the event-driven MAESTRO-NASH OUTCOMES trial, "assessing progression to liver decompensation events in patients with compensated MASH cirrhosis treated with Rezdiffra versus placebo", has results expected in 2027. The registry lists 845 patients estimated and a primary outcome of an adjudicated composite clinical event up to Month 36. source

   Our view: A fall in modeled portal hypertension risk in an open-label cohort is a hypothesis, not proof of benefit in cirrhosis. The release also lists a new patent for cirrhosis (F4c), but Rezdiffra is not approved there, and the 10-Q expects the placebo-controlled MAESTRO-NASH OUTCOMES results in 2027.

3. Press release vs filing · weight low

   Sales lead the release, the loss sits lower down

   The company said: "Second-quarter 2026 Rezdiffra ® (resmetirom) net sales of $364.3 million, representing year-over-year growth of 71%" source

   The record says: Further down, the release reports "Second-quarter 2026 net loss was $57.9 million or $1.99 per share" and operating expenses of $420.6 million, and that cash fell to $838.9 million from $988.6 million at December 31, 2025. The 10-Q adds a senior secured loan with $350.0 million outstanding and a requirement to "maintain a minimum unrestricted cash balance of $100.0 million at all times." source

   Our view: Nothing is hidden, and the company says it can fund operations beyond a year. But the bullets lead with growth, and the release shows a still-loss-making business whose cash fell by about $150 million in six months, and whose second-quarter loss included $25.0 million of one-time upfront business development expense.

4. Press release vs filing · weight low

   Growth rate slowed from the prior quarter's release

   The company said: "First-quarter 2026 Rezdiffra ® (resmetirom) net sales of $311.3 million, representing year-over-year growth of 127%" source

   The record says: The July release reports net sales of $364.3 million "representing year-over-year growth of 71%", against $212.8 million a year earlier, and says the increase was "driven by increased demand for Rezdiffra in the U.S." source

   Our view: Sequential sales still rose by about $53 million, so demand is growing. The year-over-year rate fell sharply as the comparison base grew, and the company gives no sales guidance, and neither the release nor the 10-Q gives sales guidance.

5. Legal and disclosure record · weight low

   No material litigation disclosed

   The record says: Note 11 of the 10-Q says the company "is not presently subject to any pending or threatened litigation that it believes, if determined adversely to the Company, individually, or taken together, would reasonably be expected to have a material adverse effect on its business or financial results." No securities litigation or enforcement is disclosed in the latest filing. source

   Our view: The filing's language is a materiality judgment by the company, not a statement that no claims exist. The note also says the company is from time to time a party to claims, intellectual property matters and regulatory inquiries in the ordinary course, none of which it names.

This is opinion. We compare the company's own announcements with its filings and the scientific record, and link every source. It is not an allegation of wrongdoing and not investment or legal advice. Legal items list only matters disclosed in filings or by courts and regulators. Checked Oct 23, 2026. Companies can respond through our right of reply.